GeneDx: Strong Fundamentals Intact As<br>Market Misreads Test Volume Dip

May 20, 2025

GeneDx: Strong Fundamentals Intact As
Market Misreads Test Volume Dip

GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance.The test volume dip is attributable to seasonality, adverse weather, and one fewer business day, not

by Chandra

DNA Screening, Genomics, Prudent Healthcare

Healthcare Stocks

April 28, 2025

GeneDx: Strengthening Leadership In Genomic Diagnostics

GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings.GeneDx will report Q1 2025 earnings on April 30,

by Chandra

Healthcare Stocks

Stock Market

July 22, 2024

Healthcare 2024 Second Half Outlook

The S&P Healthcare Index rose 6% in the first half of the year, while the Prudent Healthcare model portfolio gained 25%.While the healthcare index underperformed the broader market, there are

by Chandra

Healthcare Stocks

June 6, 2024

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset.Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are key revenue drivers,

by Chandra

Healthcare Stocks

May 22, 2024

Evolus: Chiseling Away At The Aesthetic Market

by Chandra

Healthcare Stocks

January 8, 2024

Healthcare Outlook 2024

The healthcare sector had a flat performance in 2023 due to unique issues.Drug price regulation will be an uphill challenge for the sector this year.Defensive healthcare industry groups should do

by Chandra

Healthcare Stocks

November 13, 2023

Biotech Stocks Ready To Roar

by Chandra

Healthcare Stocks

August 14, 2023

Second Half Outlook For Biotech Stocks

Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market.The direction of the 10-year

by Chandra

Healthcare Stocks

June 13, 2023

Akero Therapeutics: Marching On And Delivering Promising Results

Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need.The company's lead product candidate has shown promising and highly significant results

January 23, 2023

Healthcare Outlook 2023

Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to

by Chandra